Search EFSA Journal
Refine your search
Type
All article types
Special Issue Item
Journal Editorial
Scientific opinions of Scientific/Scientific Panel
Opinion of the Scientific Committee/Scientific Panel
Statement of the Scientific Committee/Scientific Panel
Guidance of the Scientific Committee/Scientific Panel
Other scientific outputs of EFSA
Statement of EFSA
Guidance of EFSA
Conclusion on pesticides
Reasoned opinion on pesticide
Scientific report of EFSA
Technical Report
Subject
All subjects
Animal health & welfare
Biological hazards
Biological monitoring
Contaminants
Dietary & chemical monitoring
Emerging risks
Feed
Food Ingredients and Packaging
GMO
Nutrition
Pesticides
Plant health
Assessment and methodological support
Scientific Committee
Scientific cooperation
Article ID
Digital Object ID
Sort by:
Publication date
Relevance

Scientific Opinion on the substantiation of health claims related to glucosamine alone or in combination with chondroitin sulphate and maintenance of joints (ID 1561, 1562, 1563, 1564, 1565) and reduction of inflammation (ID 1869) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

EFSA Journal 2009; 7(9):1264 [17 pp.]. doi:10.2903/j.efsa.2009.1264
  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) Panel Members Jean-Louis Bresson, Albert Flynn, Marina Heinonen, Karin Hulshof, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Hildegard Przyrembel, Seppo Salminen, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Henk van den Berg, Hendrik van Loveren and Hans Verhagen Contact nda@efsa.europa.eu
Type: Opinion of the Scientific Committee/Scientific Panel On request from: European Commission Question number: EFSA-Q-2008-2298 , EFSA-Q-2008-2299 , EFSA-Q-2008-2300 , EFSA-Q-2008-2301 , EFSA-Q-2008-2302 , EFSA-Q-2008-2602 Adopted: 02 July 2009 Published: 01 October 2009 Last updated: 24 November 2009. This version replaces the previous one/s. Affiliation: European Food Safety Authority (EFSA), Parma, Italy
Abstract

No abstract available

Summary

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation 1924/2006. This opinion addresses the scientific substantiation of health claims in relation to glucosamine, either as glucosamine hydrochloride or as glucosamine sulphate, either alone or in various combinations with chondroitin sulphate and the following claimed effects: maintenance of joints and reduction of inflammation. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders.

The food constituent that is the subject of the health claims is glucosamine, either as glucosamine hydrochloride or as glucosamine sulphate, either alone or in various combinations with chondroitin sulphate. The Panel considers that glucosamine, either as glucosamine hydrochloride or as glucosamine sulphate, either alone or in various combinations with chondroitin sulphate, is sufficiently characterised.

Maintenance of joints


The claimed effect is “joints health”. The Panel assumes that the target population is the general population. The Panel considers that the maintenance of normal joints is beneficial to human health.

In weighing the evidence, the Panel took into account that the evidence provided does not establish that patients with osteoarthritis are representative of the general population with respect to the status of joint tissues, or that results obtained in studies on subjects with osteoarthritis can be extrapolated to the maintenance of normal joints in the general population. The Panel also took into account that the evidence provided in the animal and in vitro studies submitted does not predict the occurrence of an effect of glucosamine intake, either as glucosamine hydrochloride or as glucosamine sulphate, either alone or in various combinations with chondroitin sulphate, on the maintenance of normal joints in humans.

On the basis of the data available, the Panel concludes that a cause and effect relationship has not been established between the consumption of glucosamine, either as glucosamine hydrochloride or as glucosamine sulphate, either alone or in combination with chondroitin sulphate and maintenance of normal joints in the general population.

Reduction of inflammation


The claimed effect is “immune system”. The Panel assumes that the target population is the general population. In the context of the proposed wordings, the Panel notes that the claimed effect relates to the reduction of inflammation. The Panel considers that under certain circumstances the reduction of inflammation might be beneficial to human health.

In weighing the evidence, the Panel took into account that the evidence provided does not establish that patients with osteoarthritis are representative of the general population with regard to the inflammatory status of the joint tissues, and that the evidence provided in the animal studies does not establish the occurrence of an effect of glucosamine sulphate intake on inflammation in humans

On the basis of the data available, the Panel concludes that cause and effect relationship has not been established between the dietary intake of glucosamine sulphate and reduction of inflammation in the general population.

Keywords

Glucosamine, chondroitin sulphate, joints, inflammation, health claims.